You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 18, 2026

avobenzone; octinoxate; oxybenzone - Profile


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for avobenzone; octinoxate; oxybenzone and what is the scope of freedom to operate?

Avobenzone; octinoxate; oxybenzone is the generic ingredient in one branded drug marketed by Bayer Healthcare Llc and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for avobenzone; octinoxate; oxybenzone
US Patents:0
Tradenames:1
Applicants:1
NDAs:1

US Patents and Regulatory Information for avobenzone; octinoxate; oxybenzone

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare Llc SHADE UVAGUARD avobenzone; octinoxate; oxybenzone LOTION;TOPICAL 020045-001 Dec 7, 1992 DISCN Yes No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for avobenzone; octinoxate; oxybenzone

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Healthcare Llc SHADE UVAGUARD avobenzone; octinoxate; oxybenzone LOTION;TOPICAL 020045-001 Dec 7, 1992 4,387,089 ⤷  Get Started Free
Bayer Healthcare Llc SHADE UVAGUARD avobenzone; octinoxate; oxybenzone LOTION;TOPICAL 020045-001 Dec 7, 1992 4,522,807 ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Investment Scenario and Fundamentals Analysis for Avobenzone, Octinoxate, and Oxybenzone

Last updated: February 3, 2026

Market Overview

The global sunscreen active ingredients market, valued at approximately $950 million in 2022, forecasts a compound annual growth rate (CAGR) of 5.5% through 2030.[1] Key drivers include rising awareness of UV damage, increased outdoor activity, and regulations targeting UV-filter safety. The market is segmented into chemical filters, with avobenzone, octinoxate, and oxybenzone leading usage in commercial formulations.

Product Profiles

  • Avobenzone (Butyl Methoxydibenzoylmethane): A UVA photoprotective agent with high efficacy; used in 80-90% of broad-spectrum sunscreens[2].

  • Octinoxate (Ethylhexyl Methoxycinnamate): A UVB filter, used in over 60% of sunscreens globally; known for absorption efficacy and cost-effectiveness.

  • Oxybenzone (Benzophenone-3): A broad-spectrum UV filter, but facing regulatory challenges; used in approximately 45-60% of sunscreen formulations.

Regulatory and Safety Environment

Recent regulatory actions impact investment prospects:

  • Oxybenzone: Banned or restricted in Hawaii, Florida, Key West, and in the European Union[3]. This limits the market for products containing oxybenzone and incentivizes reformulation or replacement.

  • Octinoxate: Banned in Hawaii and some US states due to environmental concerns, especially damage to coral reefs[4].

  • Avobenzone: Generally considered safer, but its stability issues necessitate stabilization agents, increasing formulation complexity.

Market Dynamics

The shift towards mineral filters (zinc oxide, titanium dioxide) affects chemical UV filters' market share. Consumer demand for "reef-safe" products decreases reliance on oxybenzone and octinoxate, stimulating innovation in non-nano mineral filters. Despite regulatory pressures, chemical filters remain attractive due to cost advantages and formulation flexibility.

Investment Fundamentals

  • R&D Pipelines: Companies developing novel UV filters or reformulated products to evade regulatory bans possess higher growth potential. For example, organizations working on oxybenzone alternatives with better safety profiles.

  • Intellectual Property: Patent protections around stabilized avobenzone derivatives and non-oxybenzone UV filters provide competitive advantages.

  • Manufacturing and Supply Chains: Large-scale producer capacity for avobenzone and octinoxate exists predominantly in China and India. Supply chain resilience influences pricing and margin.

  • Environmental and Safety Pressures: Increasing restrictions reduce long-term market size for oxybenzone and octinoxate but open opportunities in mineral filters and biotechnology-based UV protectants.

  • Market Concentration: Leading players include BASF, Givaudan, and Symrise. Market entry requires significant R&D and regulatory approval, creating barriers to new entrants.

Financial Considerations

  • Pricing Trends: Prices for chemical UV filters have declined marginally over past five years due to oversupply but witness upticks driven by patent protections and innovation.

  • Margins: Producers with in-house R&D and first-mover advantage in novel filters sustain higher margins.

  • Regulatory Risks: Regulatory bans can precipitate sharp revenue declines; diversification across multiple UV filters mitigates risk.

  • Consumer Trends: Growing preference for eco-friendly, reef-safe formulations shifts demand towards mineral filters, challenging chemical filter profitability.

Strategic Outlook

Investors should monitor:

  • R&D pipelines for alternative chemical filters with improved safety profiles.

  • Regulatory developments across US, EU, and Asia, especially bans on oxybenzone and octinoxate.

  • Advances in mineral filter formulations that may replace chemical filters.

  • Patent landscapes concerning stabilized avobenzone and novel UV filters.

Key Takeaways

  • The market for chemical UV filters faces regulatory headwinds, primarily affecting oxybenzone and octinoxate. Avobenzone remains relatively stable but requires stabilization modifications.

  • Innovation in non-nano mineral filters and biotech-based UV filters offers growth avenues amid regulatory restrictions.

  • Supply chain resilience and patent protections are critical factors for profitability and competitive advantage.

  • Consumer preferences for reef-safe products impact demand and product formulation strategies.

  • Diversification and active R&D investments are essential for long-term value capture.

FAQs

Q1: How will regulatory bans on oxybenzone and octinoxate affect chemical UV filter markets?
A1: They will reduce demand for these chemicals, prompting formulators to reformulate products with alternative filters or shift towards mineral filters.

Q2: Are mineral-based filters replacing chemical UV filters?
A2: Increasingly, yes. Consumers and regulators prefer mineral filters like zinc oxide and titanium dioxide due to safety and environmental considerations.

Q3: What are the main R&D opportunities in UV filters?
A3: Developing new chemical filters with improved safety, stability, and efficacy; creating biodegradable and reef-safe formulations; and engineering biotech-based UV protectants.

Q4: Which companies lead in UV filter production?
A4: BASF, Givaudan, and Symrise dominate the market, controlling significant patents and manufacturing capacity.

Q5: How do patent protections influence market dynamics?
A5: They create barriers for new entrants, enable premium pricing, and sustain R&D investments, shaping competitive advantage.


Citations

[1] MarketsandMarkets, "Sunscreen Ingredients Market," 2022.

[2] EpiSkin, "UV Filters in Sunscreens," 2021.

[3] Environmental Working Group, "Oxybenzone Restrictions," 2022.

[4] Hawaii State Legislature, "Octinoxate Ban," 2019.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.